Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer

Inclusion Criteria: * All participants (Patients and Caregivers)-Table 1 * Age 18 or older * Ability to read and respond in English * Patient Inclusion Criteria (in addition to Table 1) * Receiving care in the MGH Cancer Center * Diagnosis of advanced (stage IV) melanoma or advanced, incurable lung cancer, including stage IV non-small cell lung cancer (NSCLC), unresectable stage III NSCLC, extensive-stage small cell lung cancer. * Plan to initiate immunotherapy with an ICI (pembrolizumab, nivolumab, ipilimumab, atezolizumab or combination), per clinician documentation in the electronic health record or study staff communication with clinician * Caregiver Inclusion Criteria (in addition to Table 1) * Identified as "a supportive person involved in their cancer care" by a patient enrolled in the study Exclusion criteria * Major psychiatric condition or comorbid illness that prohibits participation in the study * Cognitive impairment that prohibits provision of informed consent or participation in the study * Pregnant women * Prisoners